NEWS
- FDA Approves SYFOVRE™ – First Treatment for Geographic Atrophy
- Nanobodies - Current Status and Prospects
- Targeted Therapies for Multiple Myeloma (MM)
- IL-6 Unveiled: From Inflammation to Breakthrough Therapeutics
- 10 Potential Blockbuster Drug Approvals in 2023
- Development of Current Four Generation ADCs And Next Generation ADCs
- Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials
- ADC Drugs: Some Challenges To Be Solved
- Claudin6 (CLDN6): A Emerging Target For Solid Tumor
- Alzheimer's Disease Drug Development: Aducanumab, Lecanemab & Donanemab